

117TH CONGRESS  
1ST SESSION

# H. R. 1193

To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, shall establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

FEBRUARY 22, 2021

Mr. BARR introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, shall establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Cardiovascular Ad-  
3 vances in Research and Opportunities Legacy Act”.

4 **SEC. 2. GRANTS FOR VALVULAR HEART DISEASE RE-**  
5 **SEARCH.**

6 Subpart 2 of part C of title IV of the Public Health  
7 Service Act (42 U.S.C. 285b et seq.) is amended by insert-  
8 ing after section 424C (42 U.S.C. 285b–7c) the following:

9 **“SEC. 424D. GRANTS FOR VALVULAR HEART DISEASE RE-**  
10 **SEARCH.**

11 “(a) IN GENERAL.—The Director of the National In-  
12 stitutes of Health, in consultation with the Director of the  
13 Institute, shall support or conduct research regarding val-  
14 vular heart disease.

15 “(b) SUPPORT GUIDELINES.—The distribution of  
16 funding authorized in subsection (a) may be used to pur-  
17 sue the following outcomes—

18 “(1) using precision medicine and advanced  
19 technological imaging to generate data on individ-  
20 uals with valvular heart disease;

21 “(2) identifying and developing a cohort of indi-  
22 viduals with valvular heart disease and available  
23 data;

24 “(3) corroborating data generated through clin-  
25 ical trials to develop a prediction model to distin-  
26 guish individuals at high risk for sudden cardiac ar-

1 rest or sudden cardiac death from valvular heart dis-  
2 ease; or

3 “(4) for other outcomes needed to acquire nec-  
4 essary data on valvular heart disease.

5 “(c) MITRAL VALVE PROLAPSE WORKSHOP.—Not  
6 later than one year after the date of the enactment of this  
7 section, the Director of the Institute shall convene a work-  
8 shop composed of subject matter experts and stakeholders  
9 to identify research needs and opportunities to develop  
10 prescriptive guidelines for treatment of individuals with  
11 mitral valve prolapse.

12 “(d) AUTHORIZATION OF APPROPRIATIONS.—For the  
13 purpose of carrying out this section, there is authorized  
14 to be appropriated \$20,000,000 for each of fiscal years  
15 2022 through 2026.”.

16 **SEC. 3. PROGRAMS OF CENTERS FOR DISEASE CONTROL**  
17 **AND PREVENTION.**

18 Part J of title III of the Public Health Service Act  
19 (42 U.S.C. 2 et seq.) is amended by inserting after section  
20 393 the following section:

21 **“SEC. 393A. PREVENTION OF SUDDEN CARDIAC DEATH AS A**  
22 **RESULT OF VALVULAR HEART DISEASE.**

23 “(a) IN GENERAL.—The Secretary, acting through  
24 the Director of the Centers for Disease Control and Pre-  
25 vention, may carry out projects to increase education,

1 awareness or diagnosis of valvular heart disease and to  
2 reduce the incidence of sudden cardiac death caused by  
3 valvular heart disease. Such projects may be carried out  
4 by the Secretary directly or through awards of grants or  
5 contracts to public or nonprofit private entities. The Sec-  
6 retary may directly (or through such awards) provide tech-  
7 nical assistance with respect to the planning, development,  
8 and operation of such projects.

9       “(b) CERTAIN ACTIVITIES.—Projects carried out  
10 under subsection (a) may include—

11               “(1) the implementation of public information  
12 and education programs for—

13                       “(A) the prevention of sudden cardiac  
14 death from valvular heart disease;

15                       “(B) broadening the awareness of the pub-  
16 lic concerning the risk factors for, the symp-  
17 toms of, and the public health consequences of  
18 valvular heart disease; and

19                       “(C) increasing screening, detection, and  
20 diagnosis of valvular heart disease; and

21               “(2) surveillance of out of hospital cardiac ar-  
22 rests to improve patient outcomes.

23       “(c) GRANT PRIORITIZATION.—The Secretary may,  
24 in awarding grants or entering into contracts pursuant to  
25 subsection (a), give priority to entities seeking to carry

1 out projects that target populations most impacted by val-  
2 vular heart disease.

3 “(d) COORDINATION OF ACTIVITIES.—The Secretary  
4 shall ensure that activities under this section are coordi-  
5 nated, as appropriate, with other agencies of the Public  
6 Health Service that carry out activities regarding valvular  
7 heart disease.

8 “(e) BEST PRACTICES.—The Secretary, acting  
9 through the Director of the Centers for Disease Control  
10 and Prevention, shall—

11 “(1) collect and analyze the findings of research  
12 conducted with respect to valvular heart disease; and

13 “(2) taking into account such findings, publish  
14 on the website of the Centers for Disease Control  
15 and Prevention best practices for physicians and  
16 other health care providers who provide care to indi-  
17 viduals with valvular heart disease.

18 “(f) AUTHORIZATION OF APPROPRIATIONS.—For the  
19 purpose of carrying out this section, there is authorized  
20 to be appropriated such sums as may be necessary for  
21 each of fiscal years 2022 through 2026.”.

○